MultiCorp Medical
A division of Multicorp International, Inc.
MultiCorp International, Inc. is focused on bringing the patented migraine medicine the company acquired a 70% stake in back in October
2014. Over the past 16 months we have contracted with several companies to further the drug to gain feedback from the FDA.

The company received a report back on our queries to the FDA and this has laid the groundwork for the company to go to Proof of
Concept clinical trials in an emergency room setting. This 4-Arm study will compare our medicine to the current one(s) in the marketplace.

The current U.S. market for migraine medications stand at over $800 Million and we’re fairly confident that since the medication we are
proposing, based on our patent, could achieve at least a 10-15% share of this market which translate to between $80-$120 Million. This is a
conservative estimate due to the near zero side effects the drug has shown in the past having been dispensed to over 1200 patients over
the last 11 years in a clinical setting. The company has high expectations this drug will become the norm in bringing relief to the migraine
sufferers here in the U.S. and eventually to the global market.

As we progress in developing this study and beginning the process, the company will look to partner with a larger pharmaceutical
company that will give us the distribution needed to bring the product to market, possible sooner than our goal of 2 years.
Migraine is an extraordinarily common disease that affects 38 million men, women and children in the United States. Almost everyone
either knows someone who has suffered from migraine, or has struggled with migraine themselves.

  • Nearly 1 in 4 U.S. households includes someone with migraine.
  • Amazingly, over 12% of the population - including children - suffers from migraine. That's more than diabetes and asthma combined!
  • About 18% of American women and 6% of men suffer from migraine.
  • Migraine is most common during the peak productive years, between the ages of 25 and 55.
  • Migraine tends to run in families. If one parent suffers from migraine, there is a 40% chance a child will suffer. If both parents suffer, the chance
    rises to 90%.

Many people do not realize how serious and debilitating migraine can be. In addition to attack-related disability, migraine interferes with a
sufferer's ability to function in everyday life, whether that is going to school or work, caring for family or enjoying social activities.

  • Migraine is the 8th most disabling illness in the world.
  • Every 10 seconds, someone in the United States goes to the emergency room with a headache or migraine.
  • While most sufferers experience attacks once or twice a month, 14 million people or about 4% have chronic daily headache, when attacks occur at
    least 15 days per month.
  • More than 90% of sufferers are unable to work or function normally during their migraine.

Migraine is not just a bad headache.

  • Migraine is an extremely debilitating collection of neurological symptoms.
  • Migraine is a severe recurring intense throbbing pain on one side of the head, although in about 1/3 of attacks, both sides are affected.
  • Attacks  are often accompanied by one or more of the following: visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light,
    touch and smell, and tingling or numbness in the extremities or face.
  • In 15-20% of attacks, other neurological symptoms occur before the actual head pain.
  • Attacks usually last between 4 and 72 hours.

For many sufferers, migraine is a chronic disease that significantly diminishes their quality of life.

  • About 14 million people experience chronic daily headache – when attacks occur at least 15 days per month.
  • For more than 90% of all sufferers, migraine interferes with their education, career and social activities.
  • Depression, anxiety, and sleep disturbances are common for those with chronic migraine.

Migraine is a public health issue with serious social and economic repercussions.

  • American employers lose more than $13 billion each year as a result of 113 million lost work days due to migraine.
  • Chronic illness – a category into which migraine can fall - is one of the country's biggest healthcare challenges, and costs an estimated $50 billion
    per year.
  • Migraine sufferers, like those who suffer from other chronic illnesses, face the consequences of high costs of medical services, too little support,
    and limited access to quality care.
  • People with migraine use about twice the medical resources –including prescription medications and office and emergency room visits– as non-
    sufferers.


Source - Migraine Research Foundation
Dear MultiCorp International, Inc. Shareholders,

These are exciting times as we move forward with the migraine medication as the sole focus for our company. The feedback we have
received from the FDA has given us a clear roadmap for taking this product through the next step. Having worked with Dr. Salehani in
collaboration with MCIC over the past 2 years in support of the  development of the migraine medicine, I know the value of Dr Salehani’s
prior studies as well as the information he was able to provide the FDA on patients he has treated with this medication, which was useful
in the generation of the FDA’s report.

We believe that the valuation on the patent warranted the company in suspending all other operations in order to focus 100% of our
energy on being a pharmaceutical and medical company. As part of that transition, I have agreed to take the position as interim CEO in
order to advance MultiCorp in these areas. I have offered my 35 years of experience in the health care industry because I feel the
migraine medicine should get FDA approval and become a significant solution for the treatment of migraine headaches.  In addition, we  
are exploring other opportunities for the company which could add to the growth and value of the company going forward. By capitalizing
on my experience and using my knowledge of the healthcare industry the company can and will identify other avenues for revenue in the
medical industry.

In the last couple of weeks, we have been in discussions with companies with the potential to facilitate the 4-arm study in the Emergency
Room setting which the FDA has stated should be the site in which our trials take place.  As I’m sure you realize, the FDA has high
expectations regarding accuracy and transparency in the conducting of and reporting of these trials, which will be time consuming and
costly.  Accordingly, we will be partnering with firms that have the experience and depth necessary in order to satisfy the standards
established by the FDA.

The response from the FDA outlines that upon successful completion of the 4-arm, proof of concept study, the medicine will be ready for
phase 3 of the clinical trials. This allows us to skip Phases 1 and 2 clinical trials in part because of previous clinical research that has been
done. Having our medication placed in Phase 3 clinical trial status automatically places a higher valuation on the patent and significantly
increases the chances of it getting final FDA approval in order to be fully commercialized. Our investment of time, money and effort in the
pre-IND has already created value for the company and our shareholders.

When the 4-arm study begins, we plan on creating an advisory panel of qualified physicians in various practice areas which will assist the
company in interpreting the study findings and assist the company in its path forward. In addition, this advisory panel can open other
opportunities in the medical field that the company has not been exposed to previously.

The company’s ultimate goal is to bring this product to market. However, should the opportunity arise wherein we can capitalize on a
potential sale to a large pharma company, the Board of Directors will fully evaluate this opportunity and do what’s best for MCIC now, and
in the future.
We plan to keep our shareholders updated through proper legal channels.  I look forward to growing this company into a leader in the
medical sector.   

Sincerely,

David Gustafson